Efficacy of sorafenib for extrahepatic recurrence of hepatocellular carcinoma after liver resection
H Yokoo, T Kamiyama, T Kakisaka, T Orimo… - Gan to Kagaku ryoho …, 2015 - europepmc.org
Sorafenib is the first molecularly targeted drug recommended as a treatment for advanced
hepatocellular carcinoma (HCC). Herein, we report the efficacy of sorafenib for extrahepatic …
hepatocellular carcinoma (HCC). Herein, we report the efficacy of sorafenib for extrahepatic …
[HTML][HTML] Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma
HB Huan, WY Lau, F Xia, KS Ma… - World Journal of …, 2014 - ncbi.nlm.nih.gov
Partial hepatectomy is still the treatment of choice aiming at a cure for patients with
hepatocellular carcinoma (HCC), provided that the patient can tolerate the treatment. For …
hepatocellular carcinoma (HCC), provided that the patient can tolerate the treatment. For …
[HTML][HTML] Sorafenib therapy following resection prolongs disease‑free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence
Y Liao, Y Zheng, W He, Q Li, J Shen… - Oncology …, 2017 - spandidos-publications.com
Sorafenib is the standard systemic treatment for patients with advanced hepatocellular
carcinoma (HCC); however, its therapeutic value in patients with HCC following resection …
carcinoma (HCC); however, its therapeutic value in patients with HCC following resection …
[HTML][HTML] Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
JG Park - Clinical and Molecular Hepatology, 2015 - ncbi.nlm.nih.gov
Methods In total, 523 patients with advanced HCC were treated with sorafenib in 3 large
tertiary referral hospitals in Korea. A survey was conducted to collect data on patients who …
tertiary referral hospitals in Korea. A survey was conducted to collect data on patients who …
The outcome of sorafenib therapy on unresectable hepatocellular carcinoma: experience of conversion and salvage hepatectomy
T Yoshimoto, S Imura, Y Morine, T Ikemoto… - Anticancer …, 2018 - ar.iiarjournals.org
Background/Aim: We report the outcomes of sorafenib therapy for advanced hepatocellular
carcinoma (HCC) in our Department. Patients and Methods: Thirty-eight patients with …
carcinoma (HCC) in our Department. Patients and Methods: Thirty-eight patients with …
Prospective observational study of sorafenib in hepatocellular carcinoma patients with very high risk of recurrence after surgery
S Seo, E Hatano, M Kanai, K Ogawa… - Anticancer …, 2022 - ar.iiarjournals.org
Background/Aim: Surgical resection remains the mainstay of treatment for hepatocellular
carcinoma (HCC). However, reducing the risk of postoperative recurrence is urgently …
carcinoma (HCC). However, reducing the risk of postoperative recurrence is urgently …
Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the …
K Tanaka, M Shimada, M Kudo - Oncology, 2014 - karger.com
Background: Little data are available on the long-term survival of patients treated with
sorafenib for advanced hepatocellular carcinoma (HCC). Summary: During a consensus …
sorafenib for advanced hepatocellular carcinoma (HCC). Summary: During a consensus …
Retrospective analysis of sorafenib efficacy and safety in Chinese patients with high recurrence rate of post-hepatic carcinectomy
D Wang, W Jia, Z Wang, T Wen, W Ding… - OncoTargets and …, 2019 - Taylor & Francis
Background There is no guideline recommendation for preventing hepatocellular carcinoma
(HCC) recurrence after hepatic resection. Moreover, an unmet need exists on the …
(HCC) recurrence after hepatic resection. Moreover, an unmet need exists on the …
[HTML][HTML] Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib
D Liu, A Liu, J Peng, Y Hu, X Feng - European Journal of Medical …, 2015 - Springer
Background To evaluate the feasibility and security of complete remission (CR) of advanced
hepatocellular carcinoma (HCC) achieved with sorafenib treatment, and investigate the …
hepatocellular carcinoma (HCC) achieved with sorafenib treatment, and investigate the …
Clinical characteristics of long-term survivors after sorafenib treatment for unresectable hepatocellular carcinoma: a Korean national multicenter retrospective cohort …
Background/Aim Sorafenib is the first systemic therapy for the treatment of advanced-stage
hepatocellular carcinoma (HCC) and progressive HCC after locoregional therapy. The aim …
hepatocellular carcinoma (HCC) and progressive HCC after locoregional therapy. The aim …